GLI1 overexpression
|
BCC
|
GLI1 overexpression
|
BCC
|
vismodegib Resistant: C3 – Early Trials
|
vismodegib Resistant: C3 – Early Trials
|
GLI1 overexpression
|
NSCLC
|
GLI1 overexpression
|
NSCLC
|
erlotinib Resistant: C3 – Early Trials
|
erlotinib Resistant: C3 – Early Trials
|
GLI1 overexpression
|
Thyroid Gland Papillary Carcinoma
|
GLI1 overexpression
|
Thyroid Gland Papillary Carcinoma
|
larotrectinib Sensitive: C4 – Case Studies
|
larotrectinib Sensitive: C4 – Case Studies
|